Thomas Friess
- Oncology top 2%
- Radiology, Nuclear Medicine and Imaging top 2%
- Molecular Biology
- Surgery top 10%
- Genetics top 5%
- Co-authors
- Werner ScheuerMax HasmannBirgit BossenmaierJosef EndlHelmut BurtscherPablo UmañaChristian KleinPaul G. Schlegel
- Topics
- Monoclonal and Polyclonal Antibodies Research (19 papers)Hip and Femur Fractures (16 papers)HER2/EGFR in Cancer Research (14 papers)
- Journals
- BloodGastroenterologyPLoS ONE
- Partner nations
- GermanySwitzerlandUnited Kingdom
In The Last Decade
Thomas Friess
50 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 80
- Oncology 1.0k
- Radiology, Nuclear Medicine and Imaging 680
- Molecular Biology 401
- Surgery 370
- Genetics 199
Countries citing papers authored by Thomas Friess
This map shows the geographic impact of Thomas Friess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Friess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Friess more than expected).
Fields of papers citing papers by Thomas Friess
This network shows the impact of papers produced by Thomas Friess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Friess. The network helps show where Thomas Friess may publish in the future.
Co-authorship network of co-authors of Thomas Friess
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Friess. A scholar is included among the top collaborators of Thomas Friess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Friess. Thomas Friess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 7 | |
| 4 | 5 | |
| 5 | AltersTraumaZentrum DGU®: Evaluation klinischer und ökonomischer Parameter: Eine Pilotstudie an einer deutschen Universitätsklinik | 1 |
| 6 | 2 | |
| 7 | 8 | |
| 8 | 27 | |
| 9 | 15 | |
| 10 | 70 | |
| 11 | 4 | |
| 12 | 85 | |
| 13 | 63 | |
| 14 | 98 | |
| 15 | 97 | |
| 16 | GA201, a novel humanized, glycoengineered EGFR antibody with enhanced ADCC and superior in vivo efficacy in xenograft models | 3 |
| 17 | Combinations of trastuzumab with either pertuzumab or bevacizumab show higher efficacy than lapatinib-based combinations against HER2-positive breast cancer xenografts progressing on trastuzumab monotherapy | 0 |
| 18 | Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. | 14 |
| 19 | Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models | 20 |
| 20 | 56 |
About Thomas Friess
Thomas Friess is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Emergency Medicine, having authored 54 papers that have together received 1.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (19 papers), Hip and Femur Fractures (16 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Oncology (1.0k citations), Radiology, Nuclear Medicine and Imaging (680 citations) and Genetics (199 citations). Thomas Friess has collaborated with scholars based in Germany, Switzerland and United Kingdom. Frequent co-authors include Werner Scheuer, Max Hasmann, Birgit Bossenmaier, Josef Endl, Helmut Burtscher, Pablo Umaña, Christian Klein, Paul G. Schlegel, Markus W. Büchler and Peter Malfertheiner. Their work appears in journals such as Blood, Gastroenterology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.